The 142nd Annual Meeting of the Pharmaceutical Society of Japan (Nagoya)
Advanced Search

Session Details

Oral Presentation(E) Pharmaceutical Health Care and Sciences

[26G-pm]Cancer-3

Sat. Mar 26, 2022 4:54 PM - 5:54 PM JST
Sat. Mar 26, 2022 7:54 AM - 8:54 AM UTC
[Room G] Exhibition Room 212 Bldg. 2: 1F
Chair: Kazunori Akimoto
4:54 PM - 5:06 PM JST(7:54 AM - 8:06 AM UTC)

[26G-pm18S]The acetogenin analog JCI-20679 suppresses glioblastoma stem cells proliferation via increasing p-AMPK protein levels and decreasing NFATc2 expression levels

○Shota Ando1, Naoto Kojima1, Chiami Moyama1, Mitsugu Fujita2, Hiromi Ii1, Susumu Nakata1 (1. Kyoto Pharm Univ, 2. Faculty of Med Kindai Univ)
5:06 PM - 5:18 PM JST(8:06 AM - 8:18 AM UTC)

[26G-pm19S]Elucidation of antitumor mechanism targeting Stat5b in mouse glioblastoma model

○Chiami Moyama1, Mitsugu Fujita2, Shota Ando1, Hiromi Ii3, Susumu Nakata3 (1. Grad. Sch. Pharm. Sci., Kyoto Pharm Univ., 2. Faculty of Med., Kindai Univ., 3. Kyoto Pharm Univ.)
5:18 PM - 5:30 PM JST(8:18 AM - 8:30 AM UTC)

[26G-pm20]Role of Selenoprotein P on the growth of glioblastoma and its significance as therapeutic target

Hikari Sugiura1, Xi Zhen1, Misaki Shimizu1, ○Takashi Toyama1, Yoshiro Saito1 (1. Graduate School of Pharmaceutical Sciences, Tohoku University)
5:30 PM - 5:42 PM JST(8:30 AM - 8:42 AM UTC)

[26G-pm21]Development of a novel anti-cancer immunotherapy based on tumor immunogenicity improvement by the interaction between abacavir and HLA-B*57:01

○Takeshi Susukida1, Shigeki Aoki2, Tomohiro Shirayanagi2, Kousei Ito2, Yoshihiro Hayakawa1 (1. Laboratory of Cancer Biology and Immunology, Section of Host Defences, Institute of Natural Medicine, University of Toyama, 2. Laboratory of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Chiba University)
5:42 PM - 5:54 PM JST(8:42 AM - 8:54 AM UTC)

[26G-pm22]An RSK inhibitor BI-D1870 suppressed the growth of acute myeloid leukemia

○Kazuhiro Katayama1 (1. Sch. Pharm., Nihon Univ.)
Back to Category List